Latest News - Allergan

Monday, March 27, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Research and Publications, Allergan

Allergan and Paratek Pharmaceuticals' Acne Drug Performs Well in Phase 3 Trials

Allergan and Paratek Pharmaceuticals, Inc.’s investigational acne drug performed well in two Phase 3 studies, the companies report. Sarecycline, a once-daily, oral, narrow spectrum tetracycli…

Read the full story

Monday, March 20, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Allergan

FDA Approved Juvéderm Vollure XC for Correction of Facial Wrinkles and Folds

The FDA has approved Allergan plc's Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. In the US piv…

Read the full story

Tuesday, March 14, 2017 | PracticalDermatology.com, Allergan

Survey Findings: Submental Region Major Pain Point for Patients

Close to 50 percent of individuals are bothered by the appearance of the area under their chin, and many alter their behavior as a result, according to a new survey commissioned by Allergan plc. …

Read the full story

Tuesday, February 14, 2017 | Acquisitions and Mergers, PracticalDermatology.com, Allergan , Cool Sculpting, Cynosure, PicoWay, Profound, Syneron, Tattoo , Zeltiq

Rumor Has It Syneron Is Next In Week of Surprising Aquisitions

Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners…

Read the full story

Monday, February 13, 2017 | Acquisitions and Mergers, PracticalDermatology.com, Allergan , Cool Sculpting, Zeltiq

Allergan to Acquire ZELTIQ for $2.47 Billion

Allergan plc  and ZELTIQ® Aesthetics, Inc. have entered into a definitive agreement under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 …

Read the full story

Thursday, January 19, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Allergan

FDA Approves RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For Persistent Facial Erythema Associated With Rosacea

The FDA has approved Allergan's RHOFADE™ cream for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that eval…

Read the full story

Tuesday, December 20, 2016 | Acquisitions and Mergers, PracticalDermatology.com, Allergan

With LifeCell Acquisition, Allergan Enters Regenerative Medicine Realm

Allergan plc has acquired the regenerative medicine company LifeCell for $2.9 billion in cash, subject to customary adjustments, Allergan reports. This acquisition combines LifeCell's products …

Read the full story

Monday, November 14, 2016 | Personnel/Company News, Allergan

Adriane M. Brown Joins Allergan’s Board of Directors

Adriane M. Brown is joining Allergan’s board of directors effective February 2017. Ms. Brown is currently President and Chief Operating Officer of Intellectual Ventures LLC, a private global …

Read the full story

Wednesday, October 26, 2016 | Personnel/Company News, Allergan

Brenton L. Saunders is Allergan’s New Chairman of the Board

Brenton L. Saunders is Allergan’s new Chairman of the Board, the company reports. Effective today, Saunders will replace Paul Bisaro, who served as Executive Chairman since July 1, 2014. …

Read the full story

Tuesday, October 25, 2016 | Acquisitions and Mergers, PracticalDermatology.com, PracticalDermatology.com, Allergan

Allergan Completes Vitae Tender Offer

Allergan completed their tender offer to purchase all outstanding shares of Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company. A tender offer occurs when an acquiring co…

Read the full story

Tuesday, October 18, 2016 | Personnel/Company News, PracticalDermatology.com, Product Launches and Updates, Allergan

Doctors Welcome VOLBELLA XC for Lips

Allergan’s JUVÉDERM VOLBELLA XC is here. The newly approved filler is now available for lip augmentation and correction of perioral rhytids in adults over the age of 21.  Physicia…

Read the full story

Thursday, October 13, 2016 | FDA Approval/Clearance, PracticalDermatology.com, Allergan

Sweden Greenlights Allergan’s Double Chin-Melting BELKYRA®

The Swedish Medical Products Agency has greenlighted Allergan’s BELKYRA® (deoxycholic acid) for submental fat reduction. BELKYRA® is already licensed in Canada, Australia, Iceland, Hu…

Read the full story

Tuesday, October 11, 2016 | Personnel/Company News, Allergan

Allergan’s New #ActuallySheCan Campaign Aims to Inspire Young Women

Allergan’s new female empowerment campaign ActuallySheCanSM provides young women with inspirational advice and stresses the importance of female mentorship. The campaign includes portraits of…

Read the full story

Wednesday, September 14, 2016 | Acquisitions and Mergers, PracticalDermatology.com, PracticalDermatology.com, Allergan

Allergan Bolsters Medical Derm Portfolio with Vitae Acquisition

Allergan plc is acquiring Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company. The move will serve to bolster Allergan’s medical dermatology pipeline, with the addition of VTP…

Read the full story

Wednesday, August 24, 2016 | Healthcare Trends, PracticalDermatology.com, Product Launches and Updates, Allergan

Kybella for Men May Mean Buh-Bye Beards

If Allergan’s double-chin melting injectable Kybella were to really take off among men, we may be seeing a lot fewer beards, jokes bearded Washington DC -- based dermatologist Terrence Keaney, …

Read the full story
Load More